Expert Point of View: ­Jonathan S. Berek, MD

Get Permission

Weekly vs every-3-week therapy is a somewhat controversial area in ovarian cancer, said formal discussant of the MITO-7 trial, ­Jonathan S. Berek, MD, Director of the Stanford Women’s Cancer Center, Palo Alto, California.

“[Japan Clinical Oncology Group (JCOG)]-16 showed a survival advantage for both progression-free and overall survival for dose-dense chemotherapy, and another study—[Gynecologic Oncology Group (GOG)] 262—is looking at this question along with bevacizumab [Avastin]. MITO-7 seems to trend toward improved survival with the weekly schedule, but a fairly high proportion of patients with low-stage disease were included in this trial, and dose-dense chemotherapy may be more relevant for more advanced-stage patients,” Dr. Berek told listeners.

Better Therapeutic Index

Quality of life was significantly better in the weekly arm (P < .0001) in MITO-7. “This shows the importance of giving therapy at the right time, because the toxicity was lower and [quality of life] was better, leading to a better therapeutic index. The results support the weekly schedule as part of practice,” Dr. Berek stated.

“We await data from other trials. Several studies are maturing within 1 to 5 years, and will help us answer the question,” he said.

Dr. Berek applauded the quality-of-life analysis of MITO-7. “It is critical to continue to analyze [quality of life] in all these trials. The choice of therapy may come down to what patients can tolerate better,” he commented. ■

Disclosure: Dr. Berek reported no potential conflicts of interest.

Related Articles

Weekly Carboplatin/Paclitaxel Improves Quality of Life, Toxicity vs Every-3-week Regimen in Advanced Ovarian Cancer

Patients with advanced ovarian cancer have similar survival outcomes thus far with a weekly regimen of carboplatin/paclitaxel vs the standard every-3-week regimen, but the weekly regimen is much better tolerated with improved quality of life, according to final results of the Multicenter Italian...




By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.